Leukoencephalopathies in Adulthood

Jan-Mendelt Tillema; Deborah L. Renaud

doi:10.1055/s-0032-1306391

Seminars in Neurology, Table of Contents

Semin Neurol 2012; 32(01): 085-094
DOI: 10.1055/s-0032-1306391

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Leukoencephalopathies in Adulthood

Authors

Jan-Mendelt Tillema

¹Department of Neurology, Mayo Clinic, Rochester, Minnesota
Deborah L. Renaud

¹Department of Neurology, Mayo Clinic, Rochester, Minnesota

²Department of Pediatrics, Mayo Clinic, Rochester, Minnesota

Abstract

The understanding of the genetic basis of late-onset leukoencephalopathies has continued to increase in recent years. The most commonly presenting leukoencephalopathies in adulthood can be late-onset manifestations of metabolic pathways. The understanding of these diagnoses is crucial to the evaluation of adult patients presenting with leukoencephalopathies. The authors provide an overview of the common leukoencephalopathies in adulthood, the current understanding of the pathology, and genetics of these disorders with typical imaging findings. When available, treatment options will be discussed.

Keywords

leukodystrophy - leukoencephalopathy - adult-onset - autosomal dominant

Full Text

References

References
1 Gieselmann V, Zlotogora J, Harris A, Wenger DA, Morris CP. Molecular genetics of metachromatic leukodystrophy. Hum Mutat 1994; 4 (4) 233-242
2 Bosch EP, Hart MN. Late adult-onset metachromatic leukodystrophy. Dementia and polyneuropathy in a 63-year-old man. Arch Neurol 1978; 35 (7) 475-477
3 Rauschka H, Colsch B, Baumann N , et al. Late-onset metachromatic leukodystrophy: genotype strongly influences phenotype. Neurology 2006; 67 (5) 859-863
4 Baumann N, Turpin JC, Lefevre M, Colsch B. Motor and psycho-cognitive clinical types in adult metachromatic leukodystrophy: genotype/phenotype relationships?. J Physiol Paris 2002; 96 (3-4) 301-306
5 Hageman AT, Gabreëls FJ, de Jong JG , et al. Clinical symptoms of adult metachromatic leukodystrophy and arylsulfatase A pseudodeficiency. Arch Neurol 1995; 52 (4) 408-413
6 Mahmood A, Berry J, Wenger DA , et al. Metachromatic leukodystrophy: a case of triplets with the late infantile variant and a systematic review of the literature. J Child Neurol 2010; 25 (5) 572-580
7 Hyde TM, Ziegler JC, Weinberger DR. Psychiatric disturbances in metachromatic leukodystrophy. Insights into the neurobiology of psychosis. Arch Neurol 1992; 49 (4) 401-406
8 Fressinaud C, Vallat JM, Masson M, Jauberteau MO, Baumann N, Hugon J. Adult-onset metachromatic leukodystrophy presenting as isolated peripheral neuropathy. Neurology 1992; 42 (7) 1396-1398
9 Coulter-Mackie MB, Applegarth DA, Toone JR, Gagnier L, Anzarut AR, Hendson G. Isolated peripheral neuropathy in atypical metachromatic leukodystrophy: a recurrent mutation. Can J Neurol Sci 2002; 29 (2) 159-163
10 Sadeh M, Kuritzky A, Ben-David E, Goldhammer Y. Adult metachromatic leukodystrophy with an unusual relapsing-remitting course. Postgrad Med J 1992; 68 (797) 192-195
11 Hohenschutz C, Eich P, Friedl W, Waheed A, Conzelmann E, Propping P. Pseudodeficiency of arylsulfatase A: a common genetic polymorphism with possible disease implications. Hum Genet 1989; 82 (1) 45-48
12 van der Knaap MS, Valk J, Barkhof F. Magnetic resonance of myelination and myelin disorders. 3rd ed. Berlin, New York: Springer; 2005
13 Eichler F, Grodd W, Grant E , et al. Metachromatic leukodystrophy: a scoring system for brain MR imaging observations. AJNR Am J Neuroradiol 2009; 30 (10) 1893-1897
14 de Hosson LD, van de Warrenburg BP, Preijers FW , et al. Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature. Bone Marrow Transplant 2011; 46 (8) 1071-1076
15 Solders G, Celsing G, Hagenfeldt L, Ljungman P, Isberg B, Ringdén O. Improved peripheral nerve conduction, EEG and verbal IQ after bone marrow transplantation for adult metachromatic leukodystrophy. Bone Marrow Transplant 1998; 22 (11) 1119-1122
16 Koç ON, Day J, Nieder M, Gerson SL, Lazarus HM, Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002; 30 (4) 215-222
17 Meuleman N, Vanhaelen G, Tondreau T , et al. Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report. Haematologica 2008; 93 (1) e11-e13
18 Wenger DA, Rafi MA, Luzi P. Molecular genetics of Krabbe disease (globoid cell leukodystrophy): diagnostic and clinical implications. Hum Mutat 1997; 10 (4) 268-279
19 Lissens W, Arena A, Seneca S , et al. A single mutation in the GALC gene is responsible for the majority of late onset Krabbe disease patients in the Catania (Sicily, Italy) region. Hum Mutat 2007; 28 (7) 742
20 Tappino B, Biancheri R, Mort M , et al. Identification and characterization of 15 novel GALC gene mutations causing Krabbe disease. Hum Mutat 2010; 31 (12) E1894-E1914
21 Fiumara A, Barone R, Arena A , et al. Krabbe leukodystrophy in a selected population with high rate of late onset forms: longer survival linked to c.121G > A (p.Gly41Ser) mutation. Clin Genet 2010;
22 Barone R, Brühl K, Stoeter P, Fiumara A, Pavone L, Beck M. Clinical and neuroradiological findings in classic infantile and late-onset globoid-cell leukodystrophy (Krabbe disease). Am J Med Genet 1996; 63 (1) 209-217
23 Wang C, Melberg A, Weis J, Månsson JE, Raininko R. The earliest MR imaging and proton MR spectroscopy abnormalities in adult-onset Krabbe disease. Acta Neurol Scand 2007; 116 (4) 268-272
24 Farina L, Bizzi A, Finocchiaro G , et al. MR imaging and proton MR spectroscopy in adult Krabbe disease. AJNR Am J Neuroradiol 2000; 21 (8) 1478-1482
25 Bajaj NP, Waldman A, Orrell R, Wood NW, Bhatia KP. Familial adult onset of Krabbe's disease resembling hereditary spastic paraplegia with normal neuroimaging. J Neurol Neurosurg Psychiatry 2002; 72 (5) 635-638
26 Mosser J, Lutz Y, Stoeckel ME , et al. The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet 1994; 3 (2) 265-271
27 Ferrer I, Aubourg P, Pujol A. General aspects and neuropathology of X-linked adrenoleukodystrophy. Brain Pathol 2010; 20 (4) 817-830
28 Singh I, Pujol A. Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis. Brain Pathol 2010; 20 (4) 838-844
29 Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 1997; 120 (Pt 8) 1485-1508
30 Matsumoto H, Hanajima R, Terao Y , et al. Efferent and afferent evoked potentials in patients with adrenomyeloneuropathy. Clin Neurol Neurosurg 2010; 112 (2) 131-136
31 Chaudhry V, Moser HW, Cornblath DR. Nerve conduction studies in adrenomyeloneuropathy. J Neurol Neurosurg Psychiatry 1996; 61 (2) 181-185
32 Eichler F, Mahmood A, Loes D , et al. Magnetic resonance imaging detection of lesion progression in adult patients with X-linked adrenoleukodystrophy. Arch Neurol 2007; 64 (5) 659-664
33 Teriitehau C, Adamsbaum C, Merzoug V, Kalifa G, Tourbah A, Aubourg P. [Subtle brain abnormalities in adrenomyeloneuropathy]. J Radiol 2007; 88 (7-8 Pt 1) 957-961
34 van Geel BM, Bezman L, Loes DJ, Moser HW, Raymond GV. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol 2001; 49 (2) 186-194
35 Dubey P, Fatemi A, Huang H , et al. Diffusion tensor-based imaging reveals occult abnormalities in adrenomyeloneuropathy. Ann Neurol 2005; 58 (5) 758-766
36 Fatemi A, Smith SA, Dubey P , et al. Magnetization transfer MRI demonstrates spinal cord abnormalities in adrenomyeloneuropathy. Neurology 2005; 64 (10) 1739-1745
37 Dubey P, Fatemi A, Barker PB , et al. Spectroscopic evidence of cerebral axonopathy in patients with “pure” adrenomyeloneuropathy. Neurology 2005; 64 (2) 304-310
38 Moser AB, Kreiter N, Bezman L , et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 1999; 45 (1) 100-110
39 Berger J, Pujol A, Aubourg P, Forss-Petter S. Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy. Brain Pathol 2010; 20 (4) 845-856
40 Sourander P, Wålinder J. Hereditary multi-infarct dementia. Morphological and clinical studies of a new disease. Acta Neuropathol 1977; 39 (3) 247-254
41 Sourander P, Wälinder J. Hereditary multi-infarct dementia. Lancet 1977; 1 (8019) 1015
42 Davous P. CADASIL: a review with proposed diagnostic criteria. Eur J Neurol 1998; 5 (3) 219-233
43 Tournier-Lasserve E, Joutel A, Melki J , et al. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19q12. Nat Genet 1993; 3 (3) 256-259
44 Bousser MG, Tournier-Lasserve E. Summary of the proceedings of the First International Workshop on CADASIL, Paris, May 19-21, 1993. Stroke 1994; 25 (3) 704-707
45 Joutel A, Corpechot C, Ducros A , et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996; 383 (6602) 707-710
46 Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. Lancet Neurol 2009; 8 (7) 643-653
47 Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Mohr JP. The natural history of CADASIL: a pooled analysis of previously published cases. Stroke 1999; 30 (6) 1230-1233
48 Dichgans M, Mayer M, Uttner I , et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 1998; 44 (5) 731-739
49 Chabriat H, Vahedi K, Iba-Zizen MT , et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Lancet 1995; 346 (8980) 934-939
50 Reyes S, Viswanathan A, Godin O , et al. Apathy: a major symptom in CADASIL. Neurology 2009; 72 (10) 905-910
51 Velizarova R, Mourand I, Serafini A, Crespel A, Gelisse P. Focal epilepsy as first symptom in CADASIL. Seizure 2011; 20 (6) 502-504
52 Chabriat H, Levy C, Taillia H , et al. Patterns of MRI lesions in CADASIL. Neurology 1998; 51 (2) 452-457
53 Ruchoux MM, Chabriat H, Bousser MG, Baudrimont M, Tournier-Lasserve E. Presence of ultrastructural arterial lesions in muscle and skin vessels of patients with CADASIL. Stroke 1994; 25 (11) 2291-2292
54 Low WC, Junna M, Börjesson-Hanson A , et al. Hereditary multi-infarct dementia of the Swedish type is a novel disorder different from NOTCH3 causing CADASIL. Brain 2007; 130 (Pt 2) 357-367
55 Yamamoto Y, Craggs L, Baumann M, Kalimo H, Kalaria RN. Review: molecular genetics and pathology of hereditary small vessel diseases of the brain. Neuropathol Appl Neurobiol 2011; 37 (1) 94-113
56 Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Goldman JE, Messing A. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 2001; 27 (1) 117-120
57 Stumpf E, Masson H, Duquette A , et al. Adult Alexander disease with autosomal dominant transmission: a distinct entity caused by mutation in the glial fibrillary acid protein gene. Arch Neurol 2003; 60 (9) 1307-1312
58 Seil FJ, Schochet Jr SS, Earle KM. Alexander's disease in an adult. Report of a case. Arch Neurol 1968; 19 (5) 494-502
59 Quinlan RA, Brenner M, Goldman JE, Messing A. GFAP and its role in Alexander disease. Exp Cell Res 2007; 313 (10) 2077-2087
60 Li R, Johnson AB, Salomons G , et al. Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease. Ann Neurol 2005; 57 (3) 310-326
61 Messing A, Brenner M. Alexander disease: GFAP mutations unify young and old. Lancet Neurol 2003; 2 (2) 75
62 Pareyson D, Fancellu R, Mariotti C , et al. Adult-onset Alexander disease: a series of eleven unrelated cases with review of the literature. Brain 2008; 131 (Pt 9) 2321-2331
63 Prust M, Wang J, Morizono H , et al. GFAP mutations, age at onset, and clinical subtypes in Alexander disease. Neurology 2011; 77 (13) 1287-1294
64 van der Knaap MS, Naidu S, Breiter SN , et al. Alexander disease: diagnosis with MR imaging. AJNR Am J Neuroradiol 2001; 22 (3) 541-552
65 van der Knaap MS, Ramesh V, Schiffmann R , et al. Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology 2006; 66 (4) 494-498
66 Farina L, Pareyson D, Minati L , et al. Can MR imaging diagnose adult-onset Alexander disease?. AJNR Am J Neuroradiol 2008; 29 (6) 1190-1196
67 Eldridge R, Anayiotos CP, Schlesinger S , et al. Hereditary adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. N Engl J Med 1984; 311 (15) 948-953
68 Coffeen CM, McKenna CE, Koeppen AH , et al. Genetic localization of an autosomal dominant leukodystrophy mimicking chronic progressive multiple sclerosis to chromosome 5q31. Hum Mol Genet 2000; 9 (5) 787-793
69 Marklund L, Melin M, Melberg A, Giedraitis V, Dahl N. Adult-onset autosomal dominant leukodystrophy with autonomic symptoms restricted to 1.5 Mbp on chromosome 5q23. Am J Med Genet B Neuropsychiatr Genet 2006; 141B (6) 608-614
70 Dos Santos MM, Grond-Ginsbach C, Aksay SS , et al. Adult-onset autosomal dominant leukodystrophy due to LMNB1 gene duplication. J Neurol 2011;
71 Melberg A, Hallberg L, Kalimo H, Raininko R. MR characteristics and neuropathology in adult-onset autosomal dominant leukodystrophy with autonomic symptoms. AJNR Am J Neuroradiol 2006; 27 (4) 904-911
72 Schwankhaus JD, Katz DA, Eldridge R, Schlesinger S, McFarland H. Clinical and pathological features of an autosomal dominant, adult-onset leukodystrophy simulating chronic progressive multiple sclerosis. Arch Neurol 1994; 51 (8) 757-766
73 Padiath QS, Saigoh K, Schiffmann R , et al. Lamin B1 duplications cause autosomal dominant leukodystrophy. Nat Genet 2006; 38 (10) 1114-1123
74 Schuster J, Sundblom J, Thuresson AC , et al. Genomic duplications mediate overexpression of lamin B1 in adult-onset autosomal dominant leukodystrophy (ADLD) with autonomic symptoms. Neurogenetics 2011; 12 (1) 65-72
75 Sundblom J, Melberg A, Kalimo H, Smits A, Raininko R. MR imaging characteristics and neuropathology of the spinal cord in adult-onset autosomal dominant leukodystrophy with autonomic symptoms. AJNR Am J Neuroradiol 2009; 30 (2) 328-335
76 Meijer IA, Simoes-Lopes AA, Laurent S , et al. A novel duplication confirms the involvement of 5q23.2 in autosomal dominant leukodystrophy. Arch Neurol 2008; 65 (11) 1496-1501
77 Lossos A, Meiner Z, Barash V , et al. Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol 1998; 44 (6) 867-872
78 Klein CJ, Boes CJ, Chapin JE , et al. Adult polyglucosan body disease: case description of an expanding genetic and clinical syndrome. Muscle Nerve 2004; 29 (2) 323-328
79 Ziemssen F, Sindern E, Schröder JM , et al. Novel missense mutations in the glycogen-branching enzyme gene in adult polyglucosan body disease. Ann Neurol 2000; 47 (4) 536-540
80 Sindern E, Ziemssen F, Ziemssen T , et al. Adult polyglucosan body disease: a postmortem correlation study. Neurology 2003; 61 (2) 263-265
81 Berkhoff M, Weis J, Schroth G, Sturzenegger M. Extensive white-matter changes in case of adult polyglucosan body disease. Neuroradiology 2001; 43 (3) 234-236
82 Klein CM, Bosch EP, Dyck PJ. Probable adult polyglucosan body disease. Mayo Clin Proc 2000; 75 (12) 1327-1331
83 Massa R, Bruno C, Martorana A, de Stefano N, van Diggelen OP, Federico A. Adult polyglucosan body disease: proton magnetic resonance spectroscopy of the brain and novel mutation in the GBE1 gene. Muscle Nerve 2008; 37 (4) 530-536
84 Klein CJ. Adult polyglucosan body disease. In: Pagon RA, Bird TD, Dolan CR, Stephens K, , eds. GeneReviews. Seattle: University of Washington; 1993
85 Milde P, Guccion JG, Kelly J, Locatelli E, Jones RV. Adult polyglucosan body disease. Arch Pathol Lab Med 2001; 125 (4) 519-522
86 Cali JJ, Hsieh CL, Francke U, Russell DW. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J Biol Chem 1991; 266 (12) 7779-7783
87 Oftebro H, Björkhem I, Skrede S, Schreiner A, Pederson JI. Cerebrotendinous xanthomatosis: a defect in mitochondrial 26-hydroxylation required for normal biosynthesis of cholic acid. J Clin Invest 1980; 65 (6) 1418-1430
88 Moghadasian MH, Salen G, Frohlich JJ, Scudamore CH. Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch Neurol 2002; 59 (4) 527-529
89 Menkes JH, Schimschock JR, Swanson PD. Cerebrotendinous xanthomatosis. The storage of cholestanol within the nervous system. Arch Neurol 1968; 19 (1) 47-53
90 Verrips A, Hoefsloot LH, Steenbergen GC , et al. Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain 2000; 123 (Pt 5) 908-919
91 Federico A, Dotti MT. Cerebrotendinous xanthomatosis: clinical manifestations, diagnostic criteria, pathogenesis, and therapy. J Child Neurol 2003; 18 (9) 633-638
92 Verrips A, Nijeholt GJ, Barkhof F , et al. Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. Brain 1999; 122 (Pt 8) 1589-1595
93 Siebner HR, Berndt S, Conrad B. Cerebrotendinous xanthomatosis without tendon xanthomas mimicking Marinesco-Sjoegren syndrome: a case report. J Neurol Neurosurg Psychiatry 1996; 60 (5) 582-585
94 Verrips A, van Engelen BG, Wevers RA , et al. Presence of diarrhea and absence of tendon xanthomas in patients with cerebrotendinous xanthomatosis. Arch Neurol 2000; 57 (4) 520-524
95 Federico A, Dotti MT, Loré F, Nuti R. Cerebrotendinous xanthomatosis: pathophysiological study on bone metabolism. J Neurol Sci 1993; 115 (1) 67-70
96 Barkhof F, Verrips A, Wesseling P , et al. Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 2000; 217 (3) 869-876
97 De Stefano N, Dotti MT, Mortilla M, Federico A. Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain 2001; 124 (Pt 1) 121-131
98 Dotti MT, Federico A, Signorini E , et al. Cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease): CT and MR findings. AJNR Am J Neuroradiol 1994; 15 (9) 1721-1726
99 Vanrietvelde F, Lemmerling M, Mespreuve M, Crevits L, De Reuck J, Kunnen M. MRI of the brain in cerebrotendinous xanthomatosis (van Bogaert-Scherer-Epstein disease). Eur Radiol 2000; 10 (4) 576-578
100 Berginer VM, Salen G, Shefer S. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. N Engl J Med 1984; 311 (26) 1649-1652
101 Federico A, Dotti MT. Treatment of cerebrotendinous xanthomatosis. Neurology 1994; 44 (11) 2218
102 Verrips A, Wevers RA, Van Engelen BG , et al. Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism 1999; 48 (2) 233-238
103 Axelsson R, Röyttä M, Sourander P, Akesson HO, Andersen O. Hereditary diffuse leucoencephalopathy with spheroids. Acta Psychiatr Scand Suppl 1984; 314: 1-65
104 Baba Y, Ghetti B, Baker MC , et al. Hereditary diffuse leukoencephalopathy with spheroids: clinical, pathologic and genetic studies of a new kindred. Acta Neuropathol 2006; 111 (4) 300-311
105 Hancock N, Poon M, Taylor B, McLean C. Hereditary diffuse leucoencephalopathy with spheroids. J Neurol Neurosurg Psychiatry 2003; 74 (9) 1345-1347
106 Keegan BM, Giannini C, Parisi JE, Lucchinetti CF, Boeve BF, Josephs KA. Sporadic adult-onset leukoencephalopathy with neuroaxonal spheroids mimicking cerebral MS. Neurology 2008; 70 (13 Pt 2) 1128-1133
107 Martinez-Saez E, Shah S, Costa C , et al. Adult onset leukodystrophy with neuroaxonal spheroids and demyelinating plaque-like lesions. Neuropathology 2011;
108 Mendes A, Pinto M, Vieira S, Castro L, Carpenter S. Adult-onset leukodystrophy with axonal spheroids. J Neurol Sci 2010; 297 (1-2) 40-45
109 Van Gerpen JA, Wider C, Broderick DF, Dickson DW, Brown LA, Wszolek ZK. Insights into the dynamics of hereditary diffuse leukoencephalopathy with axonal spheroids. Neurology 2008; 71 (12) 925-929
110 van der Knaap MS, Naidu S, Kleinschmidt-Demasters BK, Kamphorst W, Weinstein HC. Autosomal dominant diffuse leukoencephalopathy with neuroaxonal spheroids. Neurology 2000; 54 (2) 463-468
111 Marotti JD, Tobias S, Fratkin JD, Powers JM, Rhodes CH. Adult onset leukodystrophy with neuroaxonal spheroids and pigmented glia: report of a family, historical perspective, and review of the literature. Acta Neuropathol 2004; 107 (6) 481-488
112 Freeman SH, Hyman BT, Sims KB , et al. Adult onset leukodystrophy with neuroaxonal spheroids: clinical, neuroimaging and neuropathologic observations. Brain Pathol 2009; 19 (1) 39-47
113 Terada S, Ishizu H, Yokota O , et al. An autopsy case of hereditary diffuse leukoencephalopathy with spheroids, clinically suspected of Alzheimer's disease. Acta Neuropathol 2004; 108 (6) 538-545
114 Berry-Kravis E, Potanos K, Weinberg D, Zhou L, Goetz CG. Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Ann Neurol 2005; 57 (1) 144-147
115 Hagerman RJ, Leavitt BR, Farzin F , et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004; 74 (5) 1051-1056
116 Greco CM, Berman RF, Martin RM , et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006; 129 (Pt 1) 243-255
117 Jacquemont S, Hagerman RJ, Leehey M , et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003; 72 (4) 869-878
118 Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev 2004; 10 (1) 31-41
119 Jacquemont S, Hagerman RJ, Leehey MA , et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004; 291 (4) 460-469
120 Grigsby J, Brega AG, Jacquemont S , et al. Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). J Neurol Sci 2006; 248 (1-2) 227-233
121 Hall DA, Berry-Kravis E, Jacquemont S , et al. Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS). Neurology 2005; 65 (2) 299-301
122 Brunberg JA, Jacquemont S, Hagerman RJ , et al. Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. AJNR Am J Neuroradiol 2002; 23 (10) 1757-1766
123 Cohen S, Masyn K, Adams J , et al. Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome. Neurology 2006; 67 (8) 1426-1431
124 Loesch DZ, Litewka L, Brotchie P, Huggins RM, Tassone F, Cook M. Magnetic resonance imaging study in older fragile X premutation male carriers. Ann Neurol 2005; 58 (2) 326-330
125 Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 2007; 6 (1) 45-55